Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Evotec is a drug discovery alliance. It is focused on rapidly developing innovative drugs and other products with leading pharmaceutical and biotechnology companies. Its partners include Bayer, Boehringer Ingelheim, Genentech and Janssen Pharmaceuticals. In addition, Evotec has product candidates both in clinical and pre-clinical development.
Gilde obtained listed Evotec shares (Frankfurt Stock Exchange: EVT) in 2007 after Evotec acquired the French company Neuro3D for its clinical program in schizophrenia.
More Evotec news
Venture&Growth
ADCendo
Danish Therapeutics company focused on antibody-drug conjugates (ADCs) for the treatment of cancers.
Venture&Growth
Affimed
Affimed (Nasdaq: AFMD) is a German therapeutics company committed to utilizing the untapped potential of the innate immune system to restore patients’ natural ability to fight cancer. Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing
Venture&Growth
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell
